Lipodystrophy, Familial Partial
"Lipodystrophy, Familial Partial" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inherited conditions characterized by the partial loss of ADIPOSE TISSUE, either confined to the extremities with normal or increased fat deposits on the face, neck and trunk (type 1), or confined to the loss of SUBCUTANEOUS FAT from the limbs and trunk (type 2).
MeSH Number(s)
C17.800.849.391.700
C18.452.584.625.700
C18.452.880.391.700
Concept/Terms
Lipodystrophy, Familial Partial- Lipodystrophy, Familial Partial
- Familial Partial Lipodystrophies
- Lipodystrophies, Familial Partial
- Partial Lipodystrophies, Familial
- Partial Lipodystrophy, Familial
- Familial Partial Lipodystrophy
- Koberling-Dunnigan Syndrome
- Koberling Dunnigan Syndrome
Familial Partial Lipodystrophy, Type 2- Familial Partial Lipodystrophy, Type 2
- Lipodystrophy, Familial Partial, Dunnigan Type
- Lipodystrophy, Familial Partial, Type 2
- Dunnigan Syndrome
- Syndrome, Dunnigan
Below are MeSH descriptors whose meaning is more general than "Lipodystrophy, Familial Partial".
Below are MeSH descriptors whose meaning is more specific than "Lipodystrophy, Familial Partial".
This graph shows the total number of publications written about "Lipodystrophy, Familial Partial" by people in Harvard Catalyst Profiles by year, and whether "Lipodystrophy, Familial Partial" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
Below are the most recent publications written about "Lipodystrophy, Familial Partial" by people in Profiles.
-
Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2. Diabetes. 2021 09; 70(9):1970-1984.
-
Clinical utility of genomic analysis in adults with idiopathic liver disease. J Hepatol. 2019 06; 70(6):1214-1221.
-
A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations. Diabetes. 2018 06; 67(6):1086-1092.
-
FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism. Biochem Biophys Res Commun. 2018 01 01; 495(1):254-260.
-
Successful Treatment of an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass-Case Report and Literature Review. J Gastrointest Surg. 2017 04; 21(4):739-743.
-
A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. Can J Cardiol. 2014 Dec; 30(12):1649-54.
-
LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype. Endocrine. 2009 Dec; 36(3):518-23.
-
The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress. J Cell Mol Med. 2009 May; 13(5):959-71.
-
Resistance to high-fat diet-induced obesity but exacerbated insulin resistance in mice overexpressing preadipocyte factor-1 (Pref-1): a new model of partial lipodystrophy. Diabetes. 2008 Dec; 57(12):3258-66.